DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant

Information source: OHSU Knight Cancer Institute
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Cancer

Intervention: aprepitant (Drug); dexamethasone (Drug); ondansetron (Drug); placebo (Drug)

Phase: N/A

Status: Completed

Sponsored by: OHSU Knight Cancer Institute

Official(s) and/or principal investigator(s):
Joseph Bubalo, PharmD, Principal Investigator, Affiliation: OHSU Knight Cancer Institute

Summary

RATIONALE: Antiemetic drugs, such as aprepitant, ondansetron, and dexamethasone, may help lessen or prevent nausea and vomiting in patients undergoing a stem cell transplant. PURPOSE: This randomized clinical trial is studying aprepitant, ondansetron, and dexamethasone to see how well they work compared to placebo, ondansetron, and dexamethasone in preventing nausea and vomiting in patients who are undergoing a stem cell transplant.

Clinical Details

Official title: A Pilot Study of Aprepitant vs. Placebo Combined With Standard Antiemetics for the Control of Nausea and Vomiting During Hematopoietic Cell Transplatation(HCT)

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care

Primary outcome: Number of Emesis Free Participants During the Study Period.

Secondary outcome:

Safety in Transplant Population

Effects on Nausea, Appetite and Taste Changes

Pharmacokinetic Interaction

Detailed description: OBJECTIVES: Primary

- Compare the efficacy of standard antiemetic therapy comprising ondansetron and

dexamethasone combined with either aprepitant or placebo in controlling nausea and vomiting, as determined by the number of retch/emesis-free days, in patients undergoing hematopoietic stem cell transplantation. Secondary

- Determine the safety of aprepitant in these patients.

- Compare nausea, appetite, taste changes, nutritional intake, and mucositis in patients

treated with these regimens.

- Determine the pharmacokinetics of cyclophosphamide, carboxyethylphosphoramide mustard,

hydroxycyclophylamide, and aprepitant in these patients. OUTLINE: This is a randomized, placebo-controlled, single-blind, pilot study. Patients are randomized to 1 of 2 treatment arms.

- Arm I: Beginning on the first day of conditioning chemotherapy, patients receive oral

aprepitant once daily and standard antiemetic therapy comprising oral or IV ondansetron and oral dexamethasone.

- Arm II: Patients receive oral placebo once daily and standard antiemetic therapy as in

arm I. In both arms, treatment continues until day 4 after stem cell transplant in the absence of unacceptable toxicity. After completion of study therapy, patients are followed until day 18. PROJECTED ACCRUAL: A total of 40 patients (20 per treatment arm) will be accrued for this study.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion:

- 18 years of age or greater

- must be scheduled for an autologous or allogeneic bone marrow or peripheral stem cell

transplant

- Eastern Cooperative Oncology Group(ECOG) performance status < or = 2

- patients must have signed informed consent

- must be able to swallow tablets and capsules

- must be receiving a cyclophosphamide containing regimen.

Exclusion:

- patient has known sensitivity to aprepitant, ondansetron, or dexamethasone

- patient has received another investigational drug in the past 30 days

- patient has had emesis or requires antiemetic agents in the 48 hours prior to

beginning conditioning therapy

- patient has taken neurokinin-1 antagonists for 14 days prior to enrollment

- patient is pregnant, has a positive serum human chorionic gonadotropin(hCg) or is

lactating

- patient has serum creatinine level > or = 2*ULN

- patient has severe hepatic insufficiency (Child-Pugh score >9)

- patient drinks > 5 drinks/day for the last year

- patient with concurrent illness requiring systemic corticosteroid use other than

planned dexamethasone during conditioning therapy

Locations and Contacts

OHSU Knight Cancer Institute, Portland, Oregon 97239-3098, United States
Additional Information

Clinical trial summary from the National Cancer Institute's PDQ® database

Starting date: May 2004
Last updated: December 20, 2011

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015